Difference between revisions of "Polatuzumab vedotin (Polivy)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism from the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/polatuzumab-vedotin NCI Drug Dictionary]: An antibody-drug c...") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
||
| Line 22: | Line 22: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | + | ||
[[Category:Antibody-drug conjugates]] | [[Category:Antibody-drug conjugates]] | ||
[[Category:Anti-CD79B antibodies]] | [[Category:Anti-CD79B antibodies]] | ||
Revision as of 19:31, 27 February 2020
General information
Class/mechanism from the NCI Drug Dictionary: An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B-cell antigen receptor complex-associated protein beta chain (CD79B) conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. Upon administration, polatuzumab vedotin selectively binds to CD79B, a protein which is abundantly expressed on the surface of B-cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis.
Route: IV
Extravasation: neutral
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 6/10/2019: Initial approval in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.
Also known as
- Code names: DCDS4501A
- Brand name: Polivy